ABSTRACT
Objective To study the efficacy of stageⅡ/Ⅲcolon cancer postoperative adjuvant chemotherapy and survival time.Methods 108 stage Ⅱ/Ⅲ colon cancer patients with postoperative adjuvant chemotherapy were selected as the study group,and in the same period 52 stage Ⅱ/Ⅲ colon cancer patients with only simple surgery treatment were selected as the control group.The adjuvant curative effect of the two groups were analyzed and the sur-vival time was followed up.Results The patients of the two groups were followed up for 3 years.The median disease-free survival time of the study group was 18 months,disease-free survival rate was 69.44%,26 cases in recurrence and transfer,accounted for 24.07%,and 7 cases(6.48%) died;The median disease-free survival time of the control group was 12 months and the disease-free survival rate was 46.15%,18 cases in recurrence and transfer, accounted for 34.62%,and 10 cases(19.23%) died.The median disease-free survival,recurrence and transfer rate of the control group were statistically significant better than those of the control group(χ2 =8.07,4.74,all P<0.05).Postoperative adjuvant chemotherapy in patients with adverse reaction was mainly for nausea and vomiting,loss of appetite,pigmentation and hair loss up to see, but were comparatively light, and very little serious most patients could be tolerated.Conclusion The postoperative adjuvant chemotherapy for patients with stageⅡ/Ⅲcolon cancer can reduce postoperative recurrence,metastasis,improve patients'survival time,prolong patient life.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the expression pattern of CD133 and ALDH1 in colorectal cancer cells line Colo205 cultured in serum-free medium (SFM) containing recombinant human epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF).</p><p><b>METHODS</b>Colo205 cells were cultured in serum-free medium (SFM) containing human recombinant EGF and bFGF or in serum-supplemented medium (SSM). The expression of CD133 was analyzed in both groups, and CD133(+) and CD133(-) cells sorted from the SFM group using flow cytometry and observed microscopically for their growth status. The expression of CD133 and ALDH1 in CD133(+) cells and CD133(-) cells was detected by immunofluorescence assay. CD133(+) cells and CD133(-) cells were then injected subcutaneously into NOD/SCID mice and the expression of ALDH1 in the tumor tissues was detected by immunohistochemistry.</p><p><b>RESULTS</b>The cells in SFM group showed a significantly higher percentage of CD133(+) cells than those in SSM group (P<0.05). In SFM, CD133(+) cells were capable of forming tumor spheres while CD133(-) cells could not; CD133(+)cells strongly expressed CD133 and ALDH1 and CD133(-) cells did not. In mice, tumors generated by CD133(+) cells, but not by CD133(-) cells, positively expressed ALDH1.</p><p><b>CONCLUSIONS</b>CD133(+) Colo205 colorectal cancer cells in SFM containing human recombinant EGF and bFGF can form tumor spheres and strongly express ALDH1. ALDH1 may be one of the candidate markers of colorectal cancer stem cells.</p>